PTX Media related, page-1028

Well, not unless the question is asked in such a way as to not "implicate" TF (ie. not solicit reference by SYC of TF). I've just gone back and looked at a CarT engineering flowsheet and it suggests that the initial cell enhancement (of basically selecting younger cells of higher memory phenotype) is performed separately to the engineering stage of the CarT construct with transduction and expansion taking place as the closed non-viral automated system that we are working on in collab.

It does beg the question though as to whether TF and MD Anderson have expressed interest in our CellPryme platform. The fact that TFS have designed, built and already sell an entire range of equipment under the category of Cell Isolation With Dynabeads and MagniSort Technology suggests that our CP-M technology is more of a process carried out at the point of extraction and enhancement (for which equipment is already available). I could be wrong but it seems that the tools but not the precise CP-M technology is already on the market. From my research of the CP patent pending, certain aspects of our cell-enhancement technique are classed as novel but not all. Whether patented or not, success of CellPryme as a licensable platform will be dependent on marketing. And, that's where our collab (moving forward) with the likes of MD Anderson and TF (especially) will be our point of difference and point of call (potentially).